Effect of Gut Microbiome Restoration on Primary Hypertension Via FMT

Hypertension Clinical Trial

— FMT  

Official title:

Effect of Fecal Microbiota Transplantation on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration: a Randomized Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04406129
• Other study ID #: 2017-GZ10 (Part I)
• Status: Recruiting
• Phase: Early Phase 1
• Start date: March 17, 2021
• Est. completion date: September 1, 2022

Study information

• Verified date: July 2021
• Source: Chinese Academy of Medical Sciences, Fuwai Hospital
• Contact: LUYUN FAN
• Phone: 01088392165
• Email: fuwai_fanluyun[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mounting preclinical and clinical evidences have proved the causal role of gut microbiota on the pathogenesis of primary hypertension. Restoration of gut microbiota ameliorated high BP in rodents and/or human cases.A hypothesis is thus raised that gut microbiome restoration can be a potential approach to ameliorate hypertension. This pilot study will utilize fecal microbiota transplantation (FMT) capsules, in comparison with placebo capsules, to investigate the effect, safety and underlying mechanisms of gut microbiome restoration on primary hypertension.

Description:

Primary hypertension is a most prevalent cardiovascular diseases, and becomes a severe global public health issue because of the high morbidity and potential risk to other cardiovascular diseases. Several animal studies and diverse patient cohorts reported that the disorder of gut microbiome correlated with hypertension. Based on the investigators' previous work findings of metagenomics analysis, fecal transplantation and metabolomics changes in hypertension and pre-hypertension patients, a casual role of gut microbiome disorder was observed in primary hypertension and raised a hypothesis that gut microbiome restoration can be a potential approach to ameliorate hypertension. Recent studies indicated FMT, prebiotics, probiotics, dietary changes and other methodologies can assist gut microbiome restoration in diseases such as type 2 diabetes. The investigators therefore develop two pilot studies respectively utilizing FMT capsules (Pilot Study I) and innovative dietary changes (Pilot Study II) to explore the effect, safety and underlying mechanisms of gut microbiome restoration on hypertension. These pilot studies also present as the clinical translational section of the research project "The Role of Gut Microbiome in the Pathogenesis of Essential Hypertension"(Project ID 81630014, sponsored by National Natural Science Foundation of China).

This study is the Study I:

Objective: To explore the effect, safety and underlying mechanisms of gut microbiome restoration via FMT on primary hypertension.

Study Design: A multicenter, randomized, double-blinded, placebo-controlled pilot study.

Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality.

Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 1, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Age 18~60 years.

2. Established Diagnosis of Grade 1 Hypertension (initial diagnosis or free from antihypertensive drugs within a month): 140mmHg= Office SBP<160mmHg for three measurements at different days without any antihypertensive medications, according to the "2010 Chinese Guidelines for Prevention and Treatment of Hypertension".

3. Patients with informed consent after thorough explanation.

Exclusion Criteria:

1. Antibiotics or probiotics usage within last 4 weeks

2. Participants of other clinical trials related to hypertension currently or within last 3 months

3. Antihypertensive medications usage currently or within last month

4. Diagnosed secondary hypertension

5. Severe hepatic or renal diseases ((ALT >3 times the upper limit of normal value, or end stage renal disease on dialysis or eGFR <30 mL/min/1.73 m2, or serum creatinine >2.5 mg/dl [>221 µmol/L])

6. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack [TIA])

7. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 12 months.

8. Sustained atrial fibrillation or arrhythmias at recruitment disturbing the electronic BP measurement.

9. NYHA class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months.

10. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period.

11. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease.

12. Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome.

13. Cognitive impairment or severe neuropsychiatric comorbidities who are incapable of providing their own informed consent.

14. Participants preparing for or under pregnancy and/or lactation.

15. Other conditions inappropriate for recruitment according to the investigators.

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Biological:
• FMT capsules
Intervention: FMT capsules containing extensively screened donor stool.

Other:
• Placebo capsules
Intervention: Placebo capsules that do not contain donor stool or any active drug.

Locations

Country	Name	City	State
China	Fuwai Hospital, Chinese Academy of Medical Sciences	Beijing	Beijing
China	Qilu Hospital of Shandong University	Jinan	Shandong
China	Fuwai Yunnan Cardiovascular Hospital	Kunming	Yunnan
China	The Second Affiliated Hospital of Shantou University	Shantou	Guangdong
China	Southern University of Science and Technology Hospital	Shenzhen	Shenzhen
China	Shanxi Bethune Hospital	Taiyuan	Shanxi
China	The People's Hospital of Ji Xian District	Tianjin	Tianjin

Sponsors (2)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital	National Natural Science Foundation of China

Country where clinical trial is conducted

China, 

References & Publications (3)

Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljevic T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017 Apr;66(4):569-580. doi: 10.1136/gutjnl-2016-313017. Epub 2017 Jan 13. — View Citation

Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017 Feb 1;5(1):14. doi: 10.1186/s40168-016-0222-x. — View Citation

Translating Microbiome Research into Therapies: The Path Ahead. Cell. 2020 Apr 2;181(1):20-21. doi: 10.1016/j.cell.2020.03.009. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change for Office Systolic Blood Pressure (SBP)	Change for Office Systolic Blood Pressure (SBP)	From baseline to Day 30
Secondary	Change for Office SBP	Change for Office SDBP	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Change for Office Diastolic Blood Pressure (DBP)	Change for Office Diastolic Blood Pressure (DBP)	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Change for Home Systolic Blood Pressure (SBP)	Change for Home Systolic Blood Pressure (SBP)	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Change for Home Diastolic Blood Pressure (DBP)	Change for Home Diastolic Blood Pressure (DBP)	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Change for average SBP via 24-hour Ambulatory BP Monitoring	Change for average SBP via 24-hour Ambulatory BP Monitoring	Baseline, Day 30, Day 90
Secondary	Change for average DBP via 24-hour Ambulatory BP Monitoring	Change for average DBP via 24-hour Ambulatory BP Monitoring	Baseline, Day 30, Day 90
Secondary	Change for daytime average SBP via 24-hour Ambulatory BP Monitoring	Change for daytime average SBP via 24-hour Ambulatory BP Monitoring	Baseline, Day 30, Day 90
Secondary	Change for daytime average DBP via 24-hour Ambulatory BP Monitoring	Change for daytime average DBP via 24-hour Ambulatory BP Monitoring	Baseline, Day 30, Day 90
Secondary	Change for nightime average SBP via 24-hour Ambulatory BP Monitoring	Change for nightime average SBP via 24-hour Ambulatory BP Monitoring	Baseline, Day 30, Day 90
Secondary	Change for nightime average DBP via 24-hour Ambulatory BP Monitoring	Change for nightime average DBP via 24-hour Ambulatory BP Monitoring	Baseline, Day 30, Day 90
Secondary	Change for Ankle-Brachial Blood Pressure Index(ABI)	Change for ABI as an objective measurement of arterial insufficiency based on the ratio of ankle systolic pressure to brachial systolic pressure.	Baseline, Day 90
Secondary	Number of Participants with Adverse Events (AEs) as a Measure of Safety	Number of Participants with Adverse Events (AEs) as a Measure of Safety	All AEs over 3 months
Secondary	Changes in Intestinal Microbiota Composition Pre- and Post-intervention via Metagenomic Analysis	Changes in Intestinal Microbiota Composition Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by: Randomisation; Change in Office SBP	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Changes in Intestinal Microbiota Function Pre- and Post-intervention via Metagenomic Analysis	Changes in Intestinal Microbiota Function Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by: Randomisation; Change in Office SBP	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Durability of Engraftment of Donor Microbiome Following FMT	Durability of engraftment of donor microbiome following FMT, measured by similarity comparison of intestinal microbiota composition between donor and recipient	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Changes in Intestinal Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis	Changes in Intestinal Metabolite Composition Pre- and Post-intervention (FMT or Placebo) via Metabolomic Analysis, stratified by: Randomisation; Change in Office SBP	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Changes in Serum Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis	Changes in Serum Metabolite Composition Pre- and Post-intervention (FMT or Placebo) via Metabolomic Analysis, stratified by: Randomisation; Change in Office SBP	Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
Secondary	Change for Fasting Blood Glucose Level	Change for Fasting Blood Glucose Level	Baseline, Day 90
Secondary	Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)	Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)	Baseline, Day 90
Secondary	Change for Body Mass Index	Change for Body Mass Index	Baseline, Day 90